In what will probably "mark the largest healthcare merger of the year," biotech company Amgen Inc. is in advanced talks to buy pharma company Horizon Therapeutics PLC. Amgen "was the last of three
suitors standing in an auction for Horizon," according to The Wall Street Journal.
Horizon "develops medicines to treat rare autoimmune and
severe inflammatory diseases."
Read the whole story at The Wall Street Journal »